earnings
confidence high
sentiment neutral
materiality 0.75
Fulgent Genetics Q2 2026 revenue $85.4M, GAAP loss $1.05/share, revises FY revenue guidance to $330-340M
Fulgent Genetics, Inc.
- Revenue of $85.4M, up 20.1% sequentially; GAAP gross margin 30.1%.
- GAAP net loss $29.5M ($1.05 loss per share); non-GAAP loss $16.2M ($0.58 loss per share).
- Repurchased 1.5M shares for $23.8M in Q2 2026.
- Cash and investments $551.5M plus anticipated tax refund of ~$106.1M.
- Revised annual revenue guidance to $330-340M from prior range (not disclosed).